The Effect Of Antihypertensive Treatment With Lisinopril and Labetalol on Baroreflex Sensitivity in Stroke - Effect Of Lisinopril and Labetalol On BRS In Stroke

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-004231-53-GB

Enrollment

Registered

2005-02-15

Start date

2004-12-22

Completion date

Unknown

Last updated

2013-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Trade Name: Lisinopril Product Name: Lisinopril Pharmaceutical Form: Tablet INN or Proposed INN: Lisinpril Dihydrate Concentration unit: mg milligram(s) Concentration type: range Concentration number:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >18 years Clinical diagnosis of stroke Clinical indication for antihypertensive treatment Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Contraindication to trial medication (beta blockers and ace inhibitors) Clinical indication for beta blockers and ace inhibitors other than hypertension

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess the effect of Lisinopril and Labetalol on baroreflex sensitivity in patients with cerebrovascular disease.;Secondary Objective: To assess whether any changes in baroreflex sensitivity observed are associated with changes in arterial compliance.;Primary end point(s): Change in baroreflex sensitivity	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026